Home/Rare Diseases/Granulomatosis with Polyangiitis

Autoimmune & Inflammatory

Granulomatosis with Polyangiitis

Also called GPA, Wegener's Granulomatosis

Granulomatosis with Polyangiitis is a systemic necrotizing vasculitis affecting small and medium blood vessels, characterized by the triad of granulomatous inflammation, necrotizing vasculitis, and glomerulonephritis. The disease results from ANCA-associated immune mechanisms, with most patients positive for c-ANCA (anti-PR3 antibodies).

View active trialsMatch me to a trial

About Granulomatosis with Polyangiitis

Granulomatosis with Polyangiitis is a systemic necrotizing vasculitis affecting small and medium blood vessels, characterized by the triad of granulomatous inflammation, necrotizing vasculitis, and glomerulonephritis. The disease results from ANCA-associated immune mechanisms, with most patients positive for c-ANCA (anti-PR3 antibodies). The pathophysiology involves abnormal T cell and B cell function leading to generation of anti-PR3 autoantibodies and activated neutrophils that trigger vessel inflammation. The disease typically affects upper respiratory tract (sinusitis, nasal involvement with crusting and bleeding), lungs (hemoptysis, pulmonary nodules), and kidneys (necrotizing glomerulonephritis with crescent formation). Systemic features include fever, weight loss, and constitutional symptoms. Untreated disease rapidly progresses to end-stage renal disease and lung failure with high mortality. Diagnosis requires integration of clinical features, ANCA serology, and tissue histology showing granulomatous inflammation and necrotizing vasculitis.

Common Symptoms

  • Sinusitis and upper respiratory symptoms with nasal crusting and bleeding
  • Cough and hemoptysis (coughing up blood)
  • Shortness of breath from pulmonary involvement
  • Hematuria (blood in urine) and proteinuria from kidney involvement
  • Joint pain and skin rashes
  • Fever, malaise, and weight loss

Who It Affects

Granulomatosis with Polyangiitis can develop at any age but typically manifests in the fourth to sixth decades of life, with bimodal distribution peaking in the 50s-60s and with some pediatric cases. It affects males and females roughly equally. The disease occurs across all racial and ethnic groups, though higher prevalence noted in Caucasian populations. About 90% of patients with systemic GPA are c-ANCA/PR3 positive.

Getting Involved in Clinical Trials

Clinical trials for Granulomatosis with Polyangiitis focus on induction and maintenance therapy optimization, particularly examining alternatives to cyclophosphamide (including rituximab), and exploring biologic therapies targeting B cells, T cells, and complement. Trials investigate corticosteroid-sparing regimens and strategies to prevent relapses while minimizing cumulative drug toxicity. Maintenance therapy with rituximab or azathioprine after induction has improved outcomes and reduced relapse rates. Patients should consult with a rheumatologist or nephrologist experienced in ANCA vasculitis.

Trusted Sources

Active Clinical Trials for Granulomatosis with Polyangiitis

Finding trials for Granulomatosis with Polyangiitis...

Related Autoimmune & Inflammatory Conditions

Autoimmune & Inflammatory

Takayasu Arteritis

Takayasu Arteritis is a rare chronic inflammatory disease of large arteries, particularly the aorta and its branches, ca...

Autoimmune & Inflammatory

Giant Cell Arteritis

Giant Cell Arteritis is a rare inflammatory disease of large and medium-sized arteries, primarily affecting people over ...

Autoimmune & Inflammatory

Behçet Disease

Behçet Disease is a rare, chronic, recurrent vasculitis causing painful oral and genital ulcers, eye inflammation, and s...